Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- PAFSC 1st Committee to Discuss Actelion’s PAH Treatment on Feb. 20
February 9, 2015
- Panel OKs Intractable Disease Designation of Muscular Dystrophy
February 6, 2015
- NHI Price System that Would Undermine Wholesalers’ Stable Supply Ability Unacceptable: HIB Director-General
February 6, 2015
- GSK Ordered to Issue Blue Letter on Lamictal
February 5, 2015
- MHLW Plans Business Suspension Order for Novartis
February 5, 2015
- R&D Tax Credit Overhaul Likely in FY2017, but In a Way to Spur Investments: LDP’s Goto
February 4, 2015
- Action to Be Taken against Novartis “Not Yet Decided”: Health Minister
February 4, 2015
- MHLW Calls for Suspension of Manufacturing, Import of Products Using Bovine-Derived Ingredients Originating in Norway
February 4, 2015
- Dr Fukui of St. Luke’s Tapped as Health Sciences Council Chair
February 3, 2015
- MHLW Compiles Requirements for Legally Recognized Clinical Research Core Hospitals
February 3, 2015
- Review Time Targets for New Drugs Revised: PFSB
February 3, 2015
- NIID to Evaluate Prototype Strains for Cell Culture-Based Influenza Vaccines
February 3, 2015
- MHLW Orders Package Insert Revision for Zytiga to Include Hypokalemia as Significant Adverse Reaction
February 3, 2015
- Wholesalers Settled FY2014 Drug Prices with 70% of Customers at December-End: Official
February 2, 2015
- PAFSC First Committee Backs Approval of Takeda’s Once-Weekly DPP-4 Inhibitor
February 2, 2015
- PM Abe Promises to Introduce Patient-Initiated Mixed-Care System while Maintaining Universal Healthcare
January 30, 2015
- Drug Wholesalers Should Stress Annual Price Cuts “Infeasible”: Ex-Minister
January 30, 2015
- MHLW Warns of Severe Febrile Neutropenia for Cabazitaxel
January 30, 2015
- Drug Discovery Support Project for Academia to Receive 3-Fold Budget Increase in FY2015
January 30, 2015
- Chuikyo’s HTA Panel Holds First Closed-Door Meeting
January 29, 2015
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…